genengnews.com /2 weeks ago

Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion

The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its fund...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher]]>

Read source
thefdalawblog.com /2 weeks ago

The Flexibility Papers No. 3: Old Drugs, New Possibilities – Repurposing as Part of the Rare Disease Framework

By James E. Valentine & Sarah Wicks —

Read source
thefdalawblog.com /3 days ago

The Flexibility Papers No. 4: Rare Diseases Can’t Wait for Perfect Data – The Case for Adequately Documented Natural His...

By Mark A. Tobolowsky & Gayatri R. Rao & James E. Valentine —

Read source
pharmexec.com /1 month ago

<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Launches Rare Disease Framework Initiative ]]>

Read source
thefdalawblog.com /1 month ago

Rare Disease Refresh: FDA’s Rare Disease Framework Initiative

By James E. Valentine & Charles G. Raver & Frank J. Sasinowski —

Read source
thefdalawblog.com /3 weeks ago

The Flexibility Papers, No. 1: First Principles for a Rare Disease Framework

By James E. Valentine & Gayatri R. Rao & Frank J. Sasinowski —

Read source
investing.com /1 month ago

vTv Therapeutics stock jumps on FDA orphan drug status

Read source
medcitynews.com /2 days ago

FDA Approval for Sanofi Drug Marks an Important First in Rare Disease

Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this...

Read source
pharmexec.com /1 month ago

<![CDATA[Finding the Few: Combining Clinical Insight, Data and Media to Reach Patients with Rare Diseases]]>

Read source
biopharmadive.com /1 month ago

Disc’s once-spurned rare disease drug to get a second chance at approval

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

Read source
biopharmadive.com /1 month ago

Shionogi pays $2B to acquire a rare disease startup

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

Read source
medcitynews.com /3 weeks ago

BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset...

Read source
medcitynews.com /1 month ago

Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex P...

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Solving the Rare Disease Launch Paradox: Using Pre-Launch Planning and Partnership to Create]]>

Read source
medicalxpress.com /3 days ago

FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival

Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann...

Read source
thehindubusinessline.com /2 weeks ago

Indian & Dutch doctors and civil society collaborate for medicine to children with rare thyroid-linked genetic disor...

Tiratricol costs nearly €180 per tablet in Europe, but in Netherlands it can be compounded, meaning it can prepared by a pharmacist, for a fraction of that price

Read source
genengnews.com /1 month ago

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for...

Read source
medcitynews.com /2 weeks ago

Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherap...

Read source
businesstoday.in /1 day ago

From ₹9 crore to ₹2.5 lakh: How a mother’s plea sparked a Hyderabad doctor’s rare drug cost fight

AHDS is a rare genetic disorder caused by a defect in the MCT8 thyroid hormone transporter. The defect prevents thyroid hormone from entering brain cells during critical stages of...

Read source
medcitynews.com /3 weeks ago

FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market

[Sponsored] For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe...

Read source
medcitynews.com /1 month ago

Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building

Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sale...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.